A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms OUTRUN
- 21 Nov 2019 Status changed from not yet recruiting to recruiting.
- 17 Feb 2019 Planned initiation date changed from 1 Aug 2018 to 1 Mar 2019.
- 18 Apr 2018 New trial record